-
Min Investment
-
$500
-
Expected Close Date
-
September 03, 2024
-
Target Raise
-
$15.00K-$1.24M
-
Security Price
-
$2.09
- Number of Employees
- 12
- Cash
- $264,595
- Revenue
- $1,677,259
- Short Term Debt
- $7,222,643
- Cost of Goods
- $1,677,259
- Long Term Debt
- $0
- Net Income
- $1,672,096
Company Description
Deverra is a clinical-stage biotech company committed to providing universal donor treatments, opening doors for accessible & affordable immune cell therapies for cancer & other life-threatening illnesses.
Key Deal Facts
Deverra’s pioneering technology aims to reinvent the way immune cell therapies are developed & delivered. Our cell therapies are cost effective, safe & can be readily available – striving to make remission a reality for all patients.
Dilanubicel, Deverra’s lead clinical asset, has shown significantly improved remission rates in a phase 2 leukemia clinical trial with 184 patient infusions. Now, we’re just one clinical trial away from potential FDA approval.